Impaired Lymphocyte Responses in Pediatric Sepsis Vary by Pathogen Type

Robert B. Lindell, MD[1,2,3], Donglan Zhang[1,4], Jenny Bush, RNC[1], Douglas C. Wallace, PhD[4,5], Joshua D. Rabinowitz, MD, PhD[6], Wenyun Lu, PhD[6], E. John Wherry, PhD[2,7,8], Scott L. Weiss, MD, MSCE[1,3,4], Sarah E. Henrickson, MD, PhD[2,9]

[1]Division of Critical Care Medicine, Department of Anesthesia and Critical Care Medicine, Children's Hospital of Philadelphia and the University of Pennsylvania Perelman School of Medicine, Philadelphia, PA;

[2]Institute for Immunology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA;

[3]Pediatric Sepsis Program, Children's Hospital of Philadelphia, Philadelphia, PA;

[4]Center for Mitochondrial and Epigenomic Medicine, Children's Hospital of Philadelphia, Philadelphia, PA;

[5]Division of Human Genetics, Department of Pediatrics, Children's Hospital of Philadelphia and the University of Pennsylvania Perelman School of Medicine, Philadelphia, PA;

[6]Department of Chemistry, Princeton University; Princeton, NJ;

[7]Department of Systems Pharmacology and Translational Therapeutics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA;

[8]Parker Institute for Cancer Immunotherapy, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA;

[9]Division of Allergy and Immunology, Department of Pediatrics, Children's Hospital of Philadelphia and the University of Pennsylvania Perelman School of Medicine, Philadelphia, PA

Corresponding author:

Robert B. Lindell, MD

Assistant Professor of Critical Care and Pediatrics

Department of Anesthesiology and Critical Care Medicine

University of Pennsylvania Perelman School of Medicine

Children's Hospital of Philadelphia

3401 Civic Center Blvd.

Philadelphia, PA 19104

Phone: 267-426-3126

Email: LindellR@chop.edu

Sources of Funding:

Financial support was provided by the Endowed Chair, Department of Anesthesiology and Critical Care, Children's Hospital of Philadelphia and the University of Pennsylvania Perelman School of Medicine. Dr. Lindell is also supported by the Thrasher Research Fund #15351. Dr. Wallace is also supported by NIH grants NS021328, MH108592, and OD010944, U.S. Department of Defense grants W81XWH-16-1-0401 and W81XWH-21-1-0128, (PR202887.e002). Dr. Wherry is also supported by the Parker Institute for Cancer Immunotherapy which supports the cancer immunology program at UPenn, and by NIAID AI155577, AI115712, AI117950, AI108545, AI082630. Dr. Weiss is also supported by NIGMS K23GM110496 and NICHD R01HD102396. Dr. Henrickson is also supported by NIAID K08AI135091, the Burroughs Wellcome Fund CAMS, the Clinical Immunology Society, and the American Academy of Allergy, Asthma, and Immunology.

ABSTRACT

Background

Sepsis is the leading cause of death in hospitalized children worldwide. Despite its hypothesized immune-mediated mechanism, targeted immunotherapy for sepsis is not available for clinical use.

Objective

To determine the association between cytometric, proteomic, bioenergetic, and metabolomic abnormalities and pathogen type in pediatric sepsis.

Methods

Serial PBMC samples were obtained from 14 sepsis patients (34 samples) and 7 control patients for this pilot study. Flow cytometry was used to define immunophenotype, including T cell subset frequency and activation state, and assess intracellular cytokine production. Global immune dysfunction was assessed by TNF-α production capacity and monocyte HLA-DR expression. Mitochondrial function was assessed by bulk respirometry. Metabolites were measured by liquid chromatography-mass spectrometry. Results were compared by timepoint and pathogen type. For detailed Methods, please see the Methods section in this article's Online Supplement.

Results

Sepsis patients were older and had higher illness severity compared to controls; demographics were otherwise similar. Compared to controls, sepsis patients demonstrated global immune dysfunction, loss of peripheral of non-naïve $CD4^+$ T cells, and reduced PBMC mitochondrial function. Metabolomic findings in sepsis patients were most pronounced at sepsis onset and included elevated uridine and 2-dehydrogluconate and depleted citrulline. Loss of peripheral non-naïve $CD4^+$ T cells was associated with immune dysfunction and reduced cytokine production despite increased T cell activation. $CD4^+$ T cell differentiation and corresponding pro- and anti-inflammatory cytokines varied by pathogen.

Conclusion

Pediatric sepsis patients exhibit a complex, dynamic physiologic state characterized by immunometabolic dysregulation which varies by pathogen type.

CLINICAL IMPLICATIONS

Comprehensive immune monitoring in critically-ill patients using small-volume samples yields novel insights into diverse T cell responses to pediatric sepsis, which may improve future personalized therapies for these high-risk patients.

KEY WORDS

Sepsis, pediatric, T cell, immunoparalysis, flow cytometry, cytokine, mitochondria, metabolomics

ABBREVIATIONS

PBMC	Peripheral blood mononuclear cells
PIM-2	Pediatric Index of Mortality-2
PRISM-III	Pediatric Risk of Mortality-III
PELOD	Pediatric Logistic Organ Dysfunction
LPS	Lipopolysaccharide
HLA-DR	Human leukocyte antigen - DR isotype
SRC	Spare respiratory capacity
PMA	Phorbol myristate acetate
Th1 cell	Type 1 $CD4^+$ T helper cell
Th2 cell	Type 1 $CD4^+$ T helper cell
Th17 cell	Type 1 $CD4^+$ T helper cell
Tfh cell	T follicular helper cell
Treg cell	Regulatory T cell
TNF-α	Tumor necrosis factor α
IFN-γ	Interferon γ

MAIN TEXT

Introduction

Pediatric sepsis is the leading cause of death in hospitalized children worldwide (1). As in adults, sepsis in children is characterized by concurrent pro- and anti-inflammatory states with dysregulation of the innate and adaptive immune response to infection (2, 3). Critical care for sepsis is limited to antibiotics, source control, and supportive care for organ dysfunction (4). Immunocompromised patients and those who develop immune suppression in the setting of sepsis both represent high-risk clinical phenotypes, with mortality rates that exceed 50% (5, 6). Despite a hypothesized immune-mediated mechanism, successful interventional trials of targeted immunomodulation in sepsis remain elusive (7).

Previous investigations have demonstrated that focused measures indicative of innate and adaptive immune dysfunction (8-10) are associated with organ dysfunction (11) and mortality (12) in pediatric sepsis, however comprehensive analyses of immunometabolic changes are lacking and could yield therapeutic insights for these high-risk patients. Advances in immune profiling have the potential to allow new insights into the role that lymphocytes play in shaping the immune response to sepsis (13-15). Here we report on a single-center prospective, observational study of immunometabolic function in children with sepsis in which we identified sepsis-associated immune dysregulation which varied by pathogen type through longitudinal cytometric, proteomic, bioenergetic, and metabolomic assays.

Results and Discussion

<u>Study patients</u>

Fourteen patients with septic shock and seven non-infected controls were included in our study. Serial blood samples were collected from patients with sepsis and processed for peripheral blood mononuclear cell (PBMC) and plasma; in total, 34 sepsis samples and 7 control samples were obtained. Sepsis samples were collected on days 1-2, 3-5, and 8-14 after sepsis recognition. Control samples were collected from neurosurgical patients in the pediatric intensive care unit (PICU) without infection or organ dysfunction. Detailed descriptions of patient recruitment are available online and have been reported previously (16, 17).

Patient demographics, clinical characteristics, and laboratory values are summarized in Table 1. As expected, sepsis patients had higher illness severity at admission compared to controls as assessed by the Pediatric Index of Mortality-2 (PIM-2) score (18), Pediatric Risk of Mortality-III (PRISM-III) score (19), and Pediatric Logistic Organ Dysfunction (PELOD) score (20). Sepsis patients were also older than controls, but other demographics were similar. Sepsis patients more frequently received endotracheal intubation, vasoactive infusion, and corticosteroids. There was one mortality in the sepsis cohort, none among controls.

Pediatric sepsis patients exhibit global immunometabolic dysregulation

To quantify differences in lymphocyte subsets between sepsis patients and controls, we first assessed the abundance of key T cell subsets by flow cytometry (Fig. 1a). Compared to controls, the abundance of non-naïve $CD4^+$ T cells was significantly reduced in patients with bacterial sepsis (Fig. 1b). Loss of central memory $CD4^+$ T cells ($CD45RA^-/CD27^+$) was the primary driver of this finding; $CD4^+$ TEMRA cells ($CD45RA^+/CD27^-$) were increased in patients with sepsis regardless of pathogen type. Non-naïve $CD8^+$ T cell subsets were similar between sepsis and controls.

We then assessed two global markers of immune dysfunction commonly used in critical care – *ex vivo* lipopolysaccharide (LPS)-stimulated tumor necrosis factor (TNF)-α production capacity and monocyte human leukocyte antigen (HLA)-DR expression. Immunoparalysis, defined by TNF-α production capacity <200pg/ml (8), was more common in sepsis patients than controls (39% vs 0%, p=0.08). Median monocyte HLA-DR was lower at sepsis onset compared to controls (75% vs 92%, p=0.02). Cohort heterogeneity by interquartile range decreased on serial samples, and markers of immune dysfunction generally improved with sepsis recovery (Fig. 1c).

We interrogated bulk PBMC mitochondrial function using an Oroboros Oxygraph to measure spare respiratory capacity (SRC), which represents the mitochondrial bioenergetic reserve available for cells to produce ATP in response to stress-induced increase in metabolic demand (21). Median SRC was lower at sepsis onset compared to controls (4.0 vs 8.4, p=0.01). SRC improved through time and varied by pathogen type (Fig. 1d). Because the proportion of lymphocyte subsets varied between sepsis patients and controls, we constructed a generalized linear model which found no association between the relative proportion of CD4+ and CD8+ subsets (naïve, central memory, effector memory, TEMRA) in the PBMC sample and mitochondrial SRC, suggesting that differences in SRC are not confounded by shifts in cell subtypes.

Finally, we assessed plasma metabolites by liquid chromatography-mass spectrometry (Fig. 1e). In this exploratory analysis, some amino acid breakdown products including uridine ($p<0.001$) and hydroxyphenylpyruvate ($p=0.012$) and intermediate markers of glucose metabolism including 2-dehydrogluconate ($p<0.001$) and D-gluconate ($p=0.017$) were markedly elevated in patients with sepsis across timepoints compared to controls. Conversely, citrulline

was decreased in children with sepsis regardless of pathogen ($p<0.001$); citrulline deficiency has been previously associated with impaired small bowel microcirculation, nitric oxide production, and mortality in sepsis (22, 23).

Taken together, these data demonstrate that pediatric patients with sepsis develop global immunometabolic dysregulation assessed by lower TNF-α production capacity, monocyte HLA-DR expression, mitochondrial SRC, loss of peripheral non-naïve T cells, and metabolomic abnormalities.

T cell abundance and polarization in pediatric sepsis vary by pathogen type

Informed by the heterogeneity of immune abnormalities above, we then stratified T cell responses by pathogen type. Demographics and severity of illness did not vary by pathogen type. We assessed $CD4^+$ T cell differentiation by measuring intracellular cytokines via flow cytometry after phorbol myristate acetate (PMA)/ionomycin stimulation and identified $CD4^+$ T cell states based on resulting intracellular cytokine expression: Th1 (IFN-γ^+), Th2 ($IL13^+$), Th17 (IL-$17\alpha^+$), Tfh (IL-21^+), Treg ($FoxP3^+$). Th1 cells were reduced in bacterial sepsis and Th2 cells were reduced in viral sepsis compared to controls; Th17, Tfh, and Treg populations did not vary significantly (Fig. 2a). Th1 and Th2 lymphocyte abundance varied widely across serial samples (Fig. 2b). Among patients with bacterial sepsis, the proportion of $IL2^+$ non-naïve $CD4^+$ lymphocytes was lower at sepsis onset compared to controls (Fig. 2c), while the proportion of $CD38^+$ cells did not vary by pathogen type.

Both pro- and anti-inflammatory plasma cytokines were elevated at sepsis onset compared to controls and varied by pathogen type (Fig. 3). IL-6 and IL-18 were most elevated in bacterial sepsis; IFN-γ was low in this subgroup, consistent with reduced CD4+ Th1 cells in this

population. IL-10 and IL-1RA were elevated in all sepsis patients, though IL-4 was only elevated in patients with viral sepsis. Among sepsis patients, cytokine values normalized through time as organ dysfunction resolved.

Loss of peripheral non-naïve $CD4^+$ T cells is associated with immune dysfunction and characteristic immunometabolic dysregulation

In our final analysis, we examined the association between the loss of peripheral non-naïve $CD4^+$ T cells and markers of immune dysfunction in sepsis patients. The loss of peripheral non-naïve $CD4^+$ T cells is associated with both TNF-α production capacity (R=0.35, p=0.03) and monocyte HLA-DR expression (R=0.59, p<0.001; Fig. 4a). The frequency non-naïve $CD4^+$ T cells is positively associated with serum IFN-γ level (R=0.57, p<0.001) and negatively associated with CD38 expression on non-naïve $CD4^+$ T cells (R=-0.48, p=0.001), suggesting that loss of peripheral non-naïve $CD4^+$ T cells is associated with decreased T cell function despite evidence of T cell activation (Fig. 4b).

Finally, we tested the association between plasma metabolites and peripheral non-naïve $CD4^+$ lymphocytes. The loss of peripheral non-naïve $CD4^+$ T cells is associated with markers of protein catabolism (hydroxyproline, uridine, phenylalanine; Fig. 4c). Conversely, low glutamine was associated with decreased peripheral non-naïve $CD4^+$ T cells. Glutamine is an essential cofactor for T cell activation, and glutamine depletion has been associated with reduced lymphocyte proliferation, cytokine production, and lymphocyte apoptosis (24, 25).

Conclusions

We have demonstrated that pediatric sepsis is associated with characteristic immunometabolic dysregulation which vary by pathogen. Adaptive immune dysfunction in sepsis develops during a hyperinflammatory, catabolic state which is characterized by mitochondrial dysfunction and loss of peripheral non-naïve T cells. Heterogeneity in the immune response is partially explained by pathogen type, which appears to influence non-naïve T cell differentiation and function. These alternations in $CD4^+$ T cell subset frequencies which vary by pathogen suggest that the dysregulated adaptive immune response to sepsis may be pathogen-specific.

While these findings are compelling, there are several limitations to our analysis of this pilot data. Our limited number of samples and cohort heterogeneity is susceptible to type II error. Comparison of sepsis patients to controls may bias toward the null if post-surgical patients have a mild inflammatory phenotype which overlaps with the immunometabolic phenotype of sepsis patients. Because steroid exposure was common in sepsis patients regardless of pathogen type, we cannot control for this important covariate in the present study. Because metabolic and mitochondrial measurements were performed in bulk, we cannot conclusively identify the association between these findings and specific immune cell subsets. Finally, we are unable to account for repeated measures within individuals due to limited sample size.

Through this pilot study, we have established the clinical feasibility of monitoring immune health in pediatric sepsis patients using small volume samples. Immune monitoring in pediatric critical illness is currently limited to inflammatory biomarkers and cytokine analysis. Deep immune profiling and functional testing of patient samples has the potential to identify mechanisms of immune dysfunction in pediatric sepsis, paving the way for personalized immunotherapy in critically ill children.

Acknowledgements

The authors thank Florin Tuluc and Jennifer Murry from the CHOP Flow Cytometry Core Laboratory and Fang Chen and Natalka Kengle from the Center for Immunotherapies at the University of Pennsylvania for their contributions to this study.

REFERENCES

1. Rudd KE, Johnson SC, Agesa KM, Shackelford KA, Tsoi D, Kievlan DR, et al. Global, regional, and national sepsis incidence and mortality, 1990–2017: analysis for the Global Burden of Disease Study. The Lancet. 2020;395(10219):200-11.

2. Goldstein B, Giroir B, Randolph A, International Consensus Conference on Pediatric S. International pediatric sepsis consensus conference: definitions for sepsis and organ dysfunction in pediatrics. Pediatr Crit Care Med. 2005;6(1):2-8.

3. Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA. 2016;315(8):801-10.

4. Weiss SL, Peters MJ, Alhazzani W, Agus MSD, Flori HR, Inwald DP, et al. Surviving Sepsis Campaign International Guidelines for the Management of Septic Shock and Sepsis-Associated Organ Dysfunction in Children. Pediatr Crit Care Med. 2020;21(2):e52-e106.

5. Lindell RB, Nishisaki A, Weiss SL, Traynor DM, Fitzgerald JC. Risk of Mortality in Immunocompromised Children With Severe Sepsis and Septic Shock. Crit Care Med. 2020.

6. Lindell RB, Gertz SJ, Rowan CM, McArthur J, Beske F, Plunkett A, et al. High Levels of Morbidity and Mortality Among Pediatric Hematopoietic Cell Transplant Recipients With Severe Sepsis: Insights From the Sepsis PRevalence, OUtcomes, and Therapies International Point Prevalence Study. Pediatr Crit Care Med. 2017;18(12):1114-25.

7. Hotchkiss RS, Opal SM. Activating Immunity to Fight a Foe - A New Path. N Engl J Med. 2020;382(13):1270-2.

8. Hall MW, Knatz NL, Vetterly C, Tomarello S, Wewers MD, Volk HD, et al. Immunoparalysis and nosocomial infection in children with multiple organ dysfunction syndrome. Intensive Care Med. 2011;37(3):525-32.

9. Wong HR, Freishtat RJ, Monaco M, Odoms K, Shanley TP. Leukocyte subset-derived genomewide expression profiles in pediatric septic shock. Pediatr Crit Care Med. 2010;11(3):349-55.

10. Muszynski JA, Nofziger R, Greathouse K, Steele L, Hanson-Huber L, Nateri J, et al. Early adaptive immune suppression in children with septic shock: a prospective observational study. Crit Care. 2014;18(4):R145.

11. Muszynski JA, Nofziger R, Moore-Clingenpeel M, Greathouse K, Anglim L, Steele L, et al. Early Immune Function and Duration of Organ Dysfunction in Critically III Children with Sepsis. Am J Respir Crit Care Med. 2018;198(3):361-9.

12. Hall MW, Geyer SM, Guo CY, Panoskaltsis-Mortari A, Jouvet P, Ferdinands J, et al. Innate immune function and mortality in critically ill children with influenza: a multicenter study. Crit Care Med. 2013;41(1):224-36.

13. Delano MJ, Ward PA. Sepsis-induced immune dysfunction: can immune therapies reduce mortality? J Clin Invest. 2016;126(1):23-31.

14. Monneret G, Gossez M, Aghaeepour N, Gaudilliere B, Venet F. How Clinical Flow Cytometry Rebooted Sepsis Immunology. Cytometry A. 2019;95(4):431-41.

15. Gossez M, Rimmele T, Andrieu T, Debord S, Bayle F, Malcus C, et al. Proof of concept study of mass cytometry in septic shock patients reveals novel immune alterations. Sci Rep. 2018;8(1):17296.

16. Weiss SL, Zhang D, Bush J, Graham K, Starr J, Tuluc F, et al. Persistent Mitochondrial Dysfunction Linked to Prolonged Organ Dysfunction in Pediatric Sepsis. Crit Care Med. 2019.

17. Weiss SL, Zhang D, Bush J, Graham K, Starr J, Murray J, et al. Mitochondrial Dysfunction is Associated With an Immune Paralysis Phenotype in Pediatric Sepsis. Shock. 2020;54(3):285-93.

18. Slater A, Shann F, Pearson G, Paediatric Index of Mortality Study G. PIM2: a revised version of the Paediatric Index of Mortality. Intensive Care Med. 2003;29(2):278-85.

19. Pollack MM, Patel KM, Ruttimann UE. PRISM III: an updated Pediatric Risk of Mortality score. Crit Care Med. 1996;24(5):743-52.

20. Leteurtre S, Martinot A, Duhamel A, Proulx F, Grandbastien B, Cotting J, et al. Validation of the paediatric logistic organ dysfunction (PELOD) score: prospective, observational, multicentre study. Lancet. 2003;362(9379):192-7.

21. Brand MD, Nicholls DG. Assessing mitochondrial dysfunction in cells. Biochem J. 2011;435(2):297-312.

22. Wijnands KA, Castermans TM, Hommen MP, Meesters DM, Poeze M. Arginine and citrulline and the immune response in sepsis. Nutrients. 2015;7(3):1426-63.

23. Weiss SL, Haymond S, Ralay Ranaivo H, Wang D, De Jesus VR, Chace DH, et al. Evaluation of asymmetric dimethylarginine, arginine, and carnitine metabolism in pediatric sepsis. Pediatr Crit Care Med. 2012;13(4):e210-8.

24. Cruzat V, Macedo Rogero M, Noel Keane K, Curi R, Newsholme P. Glutamine: Metabolism and Immune Function, Supplementation and Clinical Translation. Nutrients. 2018;10(11).

25. van der Windt GJ, Pearce EL. Metabolic switching and fuel choice during T-cell differentiation and memory development. Immunol Rev. 2012;249(1):27-42.

TABLES

Table 1. Characteristics of sepsis patients and controls at PICU admission

Variable	Sepsis Patients (n=14)	PICU Controls (n=7)	*p* [a]
Age in years, median [IQR]	15.9 [14.6-17.6]	10.4 [10.0-14.6]	0.02
Male sex, n (%)	6 (43)	6 (86)	0.16
Non-Caucasian race, n (%)	9 (64)	3 (43)	0.40
Indication for PICU admission, n (%)			--
Sepsis, bacterial etiology	7 (50)	--	
Sepsis, viral etiology	4 (29)	--	
Sepsis, culture negative / unknown etiology	3 (21)	--	
Neurosurgery	--	7 (100)	
PIM-2 probability of death, median [IQR]	4.0 [1.0-5.9]	0.2 [0.1-1.1]	0.01
PRISM-III score, median [IQR]	12.0 [7.8-14.2]	2.0 [0.0-3.0]	<0.001
PELOD score, median [IQR]	12.0 [10.3-20.8]	0.0 [0.0-0.0]	<0.001
Steroid exposure, n (%)	6 (43)	0 (0)	0.12
Endotracheal intubation, n (%)	8 (57)	0 (0)	0.01
Vasoactive infusion, n (%)	7 (50)	0 (0)	0.01
PICU mortality, n (%)	1 (7)	0 (0)	--

[a] Wilcoxon rank-sum test for continuous variables; Fisher's exact test for categorical variables.

FIGURE LEGENDS

Figure 1. Immunometabolic dysregulation in pediatric sepsis patients. Relative abundance of major T cell subsets differ between sepsis and control and are most pronounced for patients with bacterial sepsis. Global immune dysfunction and mitochondrial dysfunction present at sepsis onset resolves on longitudinal sampling. Metabolomics findings reflect increased reactive oxygen species, amino acid breakdown products, and citrulline deficiency.

Figure 2. T cell activation and differentiation varies by pathogen type in pediatric sepsis patients.

Figure 3. Plasma cytokine levels vary by pathogen type in pediatric sepsis patients.

Figure 4. Loss of peripheral non-naïve $CD4^+$ T cells is associated with functional, proteomic, and metabolomic abnormalities in pediatric sepsis patients.


A
CD8
CD4
CD8+ 19.8
CD4+ 76.2
CD27
CD45RA
CD4+ Tcm 28.5
CD4+ Tn 56.9
CD4+ Tem 3.87
CD4+ Temra 1.01
Sepsis Etiology
Bacterial
Viral
Culture Neg.
Control
B
Tnn
Tcm
Tem
Temra
% of Total CD4+
C
LPS-stimulated TNF-α
% Monocyte HLA-DR (+)
TP 1
TP 2
TP 3
PICU Control
Sepsis Timepoint
D
Mitochondrial Spare Respiratory Capacity (SRC)
Sepsis Onset
PICU Control
TP 1
TP 2
TP 3
Sepsis Timepoint
E
Uridine
Hydroxyphenyl-pyruvate
2-Dehydro-gluconate
D-gluconate
Citrulline
Log Metabolite Level


A
Th1 (IFN-γ+)
Th2 (IL-13+)
Th17 (IL-17a+)
Tfh (IL-21+)
Treg (FOXP3+)
% of Total Non-Naive CD4+
Sepsis Etiology
Bacterial
Viral
Culture Neg.
Control
B
Th1 (IFN-γ+)
Th2 (IL-13+)
% of Total Non-Naive CD4+
TP 1
TP 2
TP 3
PICU Control
Sepsis Timepoint
C
IL-2+
CD-38+
% of Total Non-Naive CD4+


IL-6
IL-18
IFN-γ
IL-1RA
IL-4
IL-10
Cytokine Level (pg/ml)
Sepsis Etiology
Bacterial
Viral
Culture Neg.
Control


A
LPS-stimulated TNF-α
R = 0.37, p = 0.021
TNF-α production (pg/mL)
% CD4Tnn of Total CD4+
Monocyte HLA-DR
R = 0.55, p = 0.00021
HLA-DR(+) / CD14(+)
% CD4Tnn of Total CD4+
B
Serum IFN-γ
R = 0.6, p = 3.3e−05
IFN-γ Level (pg/ml)
% CD4Tnn of Total CD4+
CD-38+ T cells
R = −0.42, p = 0.0058
% CD-38+ of CD4+
% CD4Tnn of Total CD4+
C
Hydroxyproline
R = −0.37, p = 0.049
Metabolite ion count/ml
% CD4Tnn of Total CD4+
Uridine
R = −0.4, p = 0.031
Metabolite ion count/ml
% CD4Tnn of Total CD4+
Phenylalanine
R = −0.41, p = 0.028
Metabolite ion count/ml
% CD4Tnn of Total CD4+
Glutamine
R = 0.42, p = 0.023
Metabolite ion count/ml
% CD4Tnn of Total CD4+